AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17942015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (10 mg) administered at the start of each session during one therapy block
Number of subjects: 2
Study 17942015 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered during the other therapy block
Number of subjects: 2
Study 15157345 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose risperidone
Number of subjects: 34
Study 15157345 — intervention group
Group type: COMPARATOR
Intervention: Nonrisperidone group (control)
Number of subjects: 34
Study 15157345 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 34
Study 10690826 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol-brinzolamide
Number of subjects: 25
Study 10690826 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol-dorzolamide
Number of subjects: 25
Study 9038596 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 10
Study 9038596 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 10
Study 8351830 — intervention group
Group type: EXPERIMENTAL
Intervention: Convex parabolic and concave parabolic shapes
Number of subjects: 0
Study 8351830 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbolic shapes
Number of subjects: 0
Study 8351830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of curvature
Number of subjects: 0
Study 2947101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba Extract
Number of subjects: 0
Study 30868570 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 0
Study 30868570 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 0
Study 30228265 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme mixture containing peptidase, semi alkaline protease, deuterolysin, and cysteine protease derived from Aspergillus oryzae, Aspergillus melleus, Penicillium citrinum, and Carica papaya L.
Number of subjects: 0
Study 30228265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26430763 — intervention group
Group type: EXPERIMENTAL
Intervention: oPEP
Number of subjects: 27
Study 24170759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (targeting A1C <6.0%)
Number of subjects: 10251
Study 24170759 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control (targeting A1C 7.0-7.9%)
Number of subjects: 10251
Study 24170759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 10251
Study 24170759 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 10251
Study 22436365 — intervention group
Group type: EXPERIMENTAL
Intervention: 2006/07 group (n=43)
Number of subjects: 83
Study 22436365 — intervention group
Group type: COMPARATOR
Intervention: 1993/96 group (n=40)
Number of subjects: 83
Study 22436365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 20200016 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic amiodarone treatment (1 month peri-cardioversion)
Number of subjects: 158
Study 20200016 — intervention group
Group type: COMPARATOR
Intervention: Continuous amiodarone treatment
Number of subjects: 158
Study 18479924 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated reduced gravity conditions
Number of subjects: 0
Study 18479924 — intervention group
Group type: COMPARATOR
Intervention: Normal gravity conditions
Number of subjects: 0
Study 15474654 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory perceptual training software
Number of subjects: 9
Study 15474654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remediation program)
Number of subjects: 9
Study 12756491 — intervention group
Group type: EXPERIMENTAL
Intervention: finasteride
Number of subjects: 18882
Study 12756491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18882
Study 11185636 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg with digoxin
Number of subjects: 12
Study 11185636 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 12
Study 8607961 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of atropine
Number of subjects: 12
Study 8607961 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of atropine
Number of subjects: 12
Study 8607961 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of atropine
Number of subjects: 12
Study 8607961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1440310 — intervention group
Group type: EXPERIMENTAL
Intervention: Allapinin, ethacizine, ritmilen, kinilentin, obsidan, and finoptin (given alone and in combinations)
Number of subjects: 44
Study 1440310 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of drugs from the first group and those from the 2nd‐4th group
Number of subjects: 44
Study 3988416 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training with contract-relax stretching prior to beginning the session (B)
Number of subjects: 48
Study 3988416 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training with stretching added at the end of the program (C)
Number of subjects: 48
Study 3988416 — intervention group
Group type: COMPARATOR
Intervention: Regular soccer training (A)
Number of subjects: 48
Study 30957448 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with sertraline hydrochloride (25 mg daily for the first 5 days, then 50 mg daily)
Number of subjects: 60
Study 30957448 — intervention group
Group type: COMPARATOR
Intervention: Sertraline hydrochloride (25 mg daily for the first 5 days, then 50 mg daily)
Number of subjects: 60
Study 28199376 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-PACK falls prevention program
Number of subjects: 120
Study 25283680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependency
Number of subjects: 283
Study 25283680 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-criticism
Number of subjects: 283
Study 23470330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 24
Study 23470330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23470330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (in high symptomatic subjects)
Number of subjects: 24
Study 20921964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction (IER) - 2710 kJ/day for 2 days/week
Number of subjects: 107
Study 18691778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low potassium (<4 mEq/L)
Number of subjects: 561
Study 18691778 — intervention group
Group type: COMPARATOR
Intervention: Normal potassium (4-4.9 mEq/L)
Number of subjects: 561
Study 18691778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal potassium (3.5-3.9 mEq/L)
Number of subjects: 561
Study 16522906 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan from oats
Number of subjects: 47
Study 16522906 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control) group with 5 g rice starch
Number of subjects: 47
Study 14580051 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil/propofol
Number of subjects: 36
Study 14580051 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil/propofol
Number of subjects: 36
Study 11389298 — intervention group
Group type: EXPERIMENTAL
Intervention: Draft CDC manual entitled, 'Guideline for Vaccine Storage and Handling'
Number of subjects: 221
Study 11389298 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive copy of draft manual)
Number of subjects: 221
Study 9209728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES)
Number of subjects: 101
Study 9209728 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 101
Study 7950119 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 0.1%
Number of subjects: 65
Study 7950119 — intervention group
Group type: EXPERIMENTAL
Intervention: flurbiprofen 0.03%
Number of subjects: 65
Study 7950119 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study 3313757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/paracetamol/codeine combination (Myprodol; Rio Ethicals) 200 mg ibuprofen, 250 mg paracetamol, 10 mg codeine phosphate per tablet
Number of subjects: 28
Study 3313757 — intervention group
Group type: COMPARATOR
Intervention: Standard ibuprofen treatment regimen (200 mg per tablet)
Number of subjects: 28
Study 2242373 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 12
Study 31655189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 15 mg (5 mg, eight hourly)
Number of subjects: 155
Study 31655189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 31655189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 155
Study 29480399 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant dextrin (20g daily for 3 months)
Number of subjects: 62
Study 28331306 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction (IC)
Number of subjects: 22
Study 28331306 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (VM)
Number of subjects: 22
Study 25312754 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-µm thulium laser (RevoLix, n=148)
Number of subjects: 296
Study 25312754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9-µm thulium laser (vela XL, n=148)
Number of subjects: 296
Study 25312754 — intervention group
Group type: COMPARATOR
Intervention: Both groups (2-µm and 1.9-µm lasers)
Number of subjects: 296
Study 23167516 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with pulmonary rehabilitation (PRNS)
Number of subjects: 46
Study 23167516 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 46
Study 21503792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue‐assisted lymph node dissection (MBLND)
Number of subjects: 50
Study 21503792 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (Unstained)
Number of subjects: 50
Study 18351337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined deferiprone (DFP) and deferoxamine (DFO)
Number of subjects: 66
Study 18351337 — intervention group
Group type: COMPARATOR
Intervention: Daily deferiprone (DFP) only
Number of subjects: 66
Study 18351337 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO) only 5 days/week
Number of subjects: 66
Study 16551916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (single shot)
Number of subjects: 50
Study 16551916 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (continuous naropine infusion)
Number of subjects: 50
Study 16465978 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary food with added amylase-rich flour (ARF-SF)
Number of subjects: 166
Study 16465978 — intervention group
Group type: COMPARATOR
Intervention: Standard supplementary food (S-SF)
Number of subjects: 166
Study 16465978 — intervention group
Group type: COMPARATOR
Intervention: Supplementary food with added water (W-SF)
Number of subjects: 166
Study 11159241 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric 5% lidocaine
Number of subjects: 58
Study 11159241 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 58
Study 9270289 — intervention group
Group type: EXPERIMENTAL
Intervention: Three counseling sessions in a prenatal setting
Number of subjects: 199
Study 9270289 — intervention group
Group type: COMPARATOR
Intervention: Wallet-sized card listing community resources for violence
Number of subjects: 199
Study 7942933 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified niacin (up to 3,000 mg/d)
Number of subjects: 28
Study 7942933 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 28
Study 2976727 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP at 0.5 microgram/min
Number of subjects: 6
Study 2976727 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP at 1.0 microgram/min
Number of subjects: 6
Study 2976727 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP at 1.0 microgram/min (skin blood flow response)
Number of subjects: 6
Study 2976727 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 6
Study 29769247 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and strength exercise programme
Number of subjects: 494
Study 29769247 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 494
Study 27782071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve strains (B632 and BR03) for three months
Number of subjects: 40
Study 27782071 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 40
Study 24618460 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction lifestyle program with soy-based meal replacement (LSMR)
Number of subjects: 380
Study 24618460 — intervention group
Group type: COMPARATOR
Intervention: Weight-reduction lifestyle program without meal replacement (LS)
Number of subjects: 380
Study 22048987 — intervention group
Group type: EXPERIMENTAL
Intervention: Disco science (DS)
Number of subjects: 74
Study 22048987 — intervention group
Group type: COMPARATOR
Intervention: No music (NM)
Number of subjects: 74
Study 22048987 — intervention group
Group type: EXPERIMENTAL
Intervention: Achy breaky heart (ABH)
Number of subjects: 74
Study 20459742 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of household heads on the use of long-lasting insecticide-treated bed nets (LLITN)
Number of subjects: 4135
Study 20459742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 4135
Study 18822403 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced coughing
Number of subjects: 68
Study 18822403 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia (1% lidocaine)
Number of subjects: 68
Study 16792646 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdermabrasion (MDA) alone
Number of subjects: 30
Study 16792646 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdermabrasion (MDA) in conjunction with a topical retinoid
Number of subjects: 30
Study 16792646 — intervention group
Group type: COMPARATOR
Intervention: Literature review on MDA
Number of subjects: 30
Study 12808542 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle placement using techniques from Gieringer and Delagi and Perotto
Number of subjects: 10
Study 11487781 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure (Group A)
Number of subjects: 106
Study 11487781 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (Group B)
Number of subjects: 106
Study 9228878 — intervention group
Group type: EXPERIMENTAL
Intervention: G II knee brace
Number of subjects: 20
Study 7966802 — intervention group
Group type: EXPERIMENTAL
Intervention: Perivalvular banding valvuloplasty (PVBV‐A)
Number of subjects: 26
Study 7966802 — intervention group
Group type: COMPARATOR
Intervention: High ligation (HL‐A)
Number of subjects: 26
Study 3313023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASS) 2‐5 mg/kg
Number of subjects: 30
Study 3313023 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 5‐10 mg
Number of subjects: 30
Study 30742245 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 853520 with food (high-fat meal)
Number of subjects: 16
Study 30742245 — intervention group
Group type: COMPARATOR
Intervention: BI 853520 as a liquid dispersion
Number of subjects: 16
Study 28459407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with fiberoptic bronchoscopy combined with vibration sputum drainage
Number of subjects: 286
Study 28459407 — intervention group
Group type: COMPARATOR
Intervention: Bronchoalveolar lavage with fiberoptic bronchoscopy
Number of subjects: 286
Study 25844615 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium copper chlorophyllin complex (0.066%) applied twice daily for 8 weeks
Number of subjects: 10
Study 25844615 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium copper chlorophyllin complex (0.066%)
Number of subjects: 10
Study 23579907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue scraping
Number of subjects: 20
Study 23579907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue brushing
Number of subjects: 20
Study 21372576 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 19
Study 20040554 — intervention group
Group type: EXPERIMENTAL
Intervention: G. biloba 120 mg twice daily (n = 1545)
Number of subjects: 3069
Study 20040554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1524)
Number of subjects: 3069
Study 20040554 — intervention group
Group type: EXPERIMENTAL
Intervention: G. biloba 120 mg twice daily
Number of subjects: 3069
Study 20040554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study 17605796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra short stay programme
Number of subjects: 160
Study 17605796 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 160
Study 15497666 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 125 mg/5 mL (Klaromin)
Number of subjects: 0
Study 15497666 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 250 mg/5 mL (Klaromin)
Number of subjects: 0
Study 15497666 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-hydroxy-clarithromycin
Number of subjects: 0
Study 11673819 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 148
Study 11673819 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART + ALVAC-HIV (vCP1452)
Number of subjects: 148
Study 11673819 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART + ALVAC-HIV (vCP1452) + Remune
Number of subjects: 148
Study 9844553 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice schedule
Number of subjects: 0
Study 9844553 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice schedule
Number of subjects: 0
Study 7986152 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 44
Study 7986152 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 44
Study 2590624 — intervention group
Group type: EXPERIMENTAL
Intervention: Riflux Forte
Number of subjects: 68
Study 2590624 — intervention group
Group type: COMPARATOR
Intervention: Riflux
Number of subjects: 68
Study 5420239 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 211
Study 5420239 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (Control)
Number of subjects: 211
Study 31750676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentives ($1/day)
Number of subjects: 75
Study 31750676 — intervention group
Group type: EXPERIMENTAL
Intervention: Charitable donations ($1/day)
Number of subjects: 75
Study 31750676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentives)
Number of subjects: 75
Study 30380175 — intervention group
Group type: EXPERIMENTAL
Intervention: Left DLPFC tSMS
Number of subjects: 24
Study 30380175 — intervention group
Group type: EXPERIMENTAL
Intervention: Right DLPFC tSMS
Number of subjects: 24
Study 30380175 — intervention group
Group type: COMPARATOR
Intervention: Sham tSMS
Number of subjects: 24
Study 28970071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 34
Study 28970071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28970071 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 34
Study 26454660 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Phobia Inventory (SPIN)
Number of subjects: 397
Study 23842584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support (PSinit)
Number of subjects: 19
Study 23842584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support (PSbest)
Number of subjects: 19
Study 23842584 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Number of subjects: 19
Study 21945737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate injection
Number of subjects: 0
Study 21945737 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibandronate infusion
Number of subjects: 0
Study 21945737 — intervention group
Group type: COMPARATOR
Intervention: Weekly oral alendronate
Number of subjects: 0
Study 19801235 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (30%)
Number of subjects: 0
Study 19801235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (35%)
Number of subjects: 0
Study 16717335 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine (15-mL bolus, starting concentration 0.425%)
Number of subjects: 2
Study 14699020 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg), vitamin B12 (0.4 mg), and vitamin B6 (40 mg)
Number of subjects: 90
Study 14699020 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) and vitamin B12 (0.4 mg)
Number of subjects: 90
Study 14699020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 alone (40 mg)
Number of subjects: 90
Study 14699020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 14699020 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after 3 months of intervention
Number of subjects: 90
Study 11704086 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-day regimen
Number of subjects: 703
Study 11704086 — intervention group
Group type: COMPARATOR
Intervention: 21-day regimen
Number of subjects: 703
Study 11704086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 703
Study 8976239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 77
Study 8976239 — intervention group
Group type: COMPARATOR
Intervention: Electroejaculation
Number of subjects: 77
Study 8823220 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2218871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus cyclophosphamide, methotrexate, and 5-fluorouracil
Number of subjects: 311
Study 2218871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 311